|List |< first << previous [record 17 of 30] next >> last >||
|Coordinate||121,251,868 bp (GRCm38)|
|Base Change||C ⇒ A (forward strand)|
|Gene Name||transformation related protein 53 binding protein 1|
|Chromosomal Location||121,193,281-121,271,407 bp (-)|
|MGI Phenotype||PHENOTYPE: Homozygous mutations in this gene result in growth retardation, immunodeficiency, thymic hypoplasia, and increased incidence of thymic lymphomas. [provided by MGI curators]|
|Amino Acid Change||Alanine changed to Serine|
|Institutional Source||Beutler Lab|
|Gene Model||predicted gene model for protein(s): [ENSMUSP00000106277] [ENSMUSP00000106278] [ENSMUSP00000120451] [ENSMUSP00000114457]|
AA Change: A317S
|Predicted Effect||probably null
PolyPhen 2 Score 0.020 (Sensitivity: 0.95; Specificity: 0.80)
AA Change: A317S
|Predicted Effect||probably null
PolyPhen 2 Score 0.027 (Sensitivity: 0.95; Specificity: 0.81)
|Predicted Effect||probably benign
PolyPhen 2 Score 0.138 (Sensitivity: 0.92; Specificity: 0.86)
AA Change: A317S
|Predicted Effect||probably null
PolyPhen 2 Score 0.125 (Sensitivity: 0.93; Specificity: 0.86)
|Alleles Listed at MGI|
|Mode of Inheritance||Autosomal Recessive|
|Local Stock||Live Mice|
|Last Updated||2018-03-08 5:07 PM by Diantha La Vine|
|Record Created||2013-08-20 7:13 PM by Kuan-Wen Wang|
The lentil phenotype was initially identified among G3 mice of the pedigree R0522, some of which exhibit a decrease in the mean fluorescence intensity (MFI) of IgD on B cells in the peripheral blood (1) (Figure 1). The lentil mice exhibit reduced levels of other immunoglobulins compared to wild-type mice (1) (Figure 2).
|Nature of Mutation|
Whole exome HiSeq sequencing of the G1 grandsire identified 65 mutations. The reduced IgD MFI phenotype was linked by continuous variable mapping to mutations in Trp53bp1, Pla2g4b, and Gpr176 (Figure 3). A CRISPR-mediated Trp53bp1 knockout mouse model recapitulated the lentil phenotype, confirming that Trp53bp1 is the causative mutation in lentil (P = 1.003 x 10-14; Figure 4). The mutation in Trp53bp1: a G to T transversion at base pair 121,251,868 (v38) on chromosome 2, or base pair 23,096 in the GenBank genomic region NC_000068. Linkage was found with a recessive model of inheritance (P = 1.715 x 10-6), wherein 10 affected variant homozygotes departed phenotypically from 10 homozygous reference mice and 19 heterozygous mice. The mutation corresponds to residue 1,078 in the mRNA sequence NM_013735 within exon 8 of 28 total exons.
RT-PCR and sequencing analysis were used to examine Trp53bp1 splicing in lentil blood. Using primers spanning exons 6-9 (5’-CTTCATCACAGTTGGGCTTTGG-3’; 5’-GTGGAAAGACTCTCCTGAACAAGG-3’) (Figure 5A), RT-PCR showed a smaller molecular weight Trp53bp1 band in the blood of homozygous lentil mice than that in wild-type mice (Figure 5B). Sequence analysis (primer: 5’-CTTTGGAGTTCTGGAACTGTCC-3’) determined that the cDNA amplified from lentil blood contained a 106-bp deletion within the 167-bp exon 8 (ENSMUST00000110648), indicating that the lentil mutation abolishes the function of the intron 8 donor splice site. The predicted mutation effect is illustrated, below. The 106-bp deletion within exon 8 results in a frameshift that creates a premature stop codon in exon 11 (aberrant amino acids after position 285, truncation after position 362).
The donor splice site within intron 8 is shown in blue and the mutated nucleotide is indicated in red.
Trp53bp1 (transformation related protein 53 binding protein 1) encodes 53BP1, a protein initially identified as one of two binding partners of p53 (2). 53BP1 has two tandem Tudor domains at amino acids 1475-1575 (3) (alternatively, amino acids 1469-1574 (4) or amino acids 1480-1601, SMART) [Figure 6; (5;6)]. The Tudor domains are required for several 53BP1-mediated functions including immunoglobulin (Ig) class switch recombination (CSR), non-homologous end joining (NHEJ), and DNA end protection (7;8). It has not been determined if the Tudor domains are required for the checkpoint or tumor suppression functions of 53BP1 (7). See the “Background” section for more details on the functions of 53BP1.
The Tudor domains are members of the SH3-like superfold family and are often found in proteins with functions in signal transduction, nucleic acid binding, transcriptional regulation, chromatin remodeling, and DNA repair (3;9). The solution structure of a 53BP1 fragment containing the mouse tandem Tudor domains (amino acids 1463-1617) has been solved using nuclear magnetic resonance (NMR) [Figure 7; PDB:1SSF; (3)]. The Tudor domains have three structural motifs corresponding to amino acids 1475-1520, 1527-1575, and 1576-1586 (3). The first and second motifs contain two strongly bent antiparallel β sheets and are tightly packed into a β-barrel-like fold connected by a six-residue linker, while the third motif forms an α-helix (3). Gly1508 in motif 1 and Gly1562 in motif 2 mediate the formation of β-turns between the third and fourth β-strands (3). 53BP1 can bind to either linear double- or single-strand DNA substrates (3). DNA binds to the 53BP1 tandem Tudor domain fragment through a surface formed by loops β1β2 and β3β4 in motif 1 (3). Loop β1β2 of motif 1 is also involved in the interaction with RG-rich peptides (3). The structure of motif 2 is affected by DNA binding, indicating that it is also involved in DNA binding (3).
The 53BP1 Tudor domains interact with methylated histone residues at the sites of double-strand DNA breaks (DSBs) (3;6). Huyen et al. determined that the 53BP1 Tudor domain binds to constitutively di-methylated histone H3 at lysine 79 (H3K79me2) both in vitro and in vivo to mediate focal recruitment (6). In a separate study, Botuyan et al. determined that the 53BP1 Tudor domains associate with constitutively di-methylated histone H4 at lysine 20 (H4K20me2) with strong affinity, but an association with H3K79me2 was negligible (10;11). Fitzgerald et al. propose that the different findings in these studies is due to genomic instability generated during transformation that altered the relative importance of H3K79me2 and H4K20me2 in the transformed cell lines used [reviewed in (12)]. In higher eukaryotes, H4K20me2 and H3K79me2 may have overlapping or redundant roles [reviewed in (12)]. Asp1521 (human 53BP1) is required for 53BP1 association with H4K20me2 and subsequent 53BP1-associated formation of DNA damage foci in response to ionizing radiation (IR) and CSR (10). The solution structure of the human Tudor domain in complex with a H4K20me2 peptide (residues 14-27) has been solved by NMR [PDB:2LVM; (13)]. After binding of the H4K20me2peptide, the chemical shifts of Tyr1502, Phe1519, Asp1521, and Tyr1523 changed (13). Tang et al. noted that Tyr1502, Phe1519, Asp1521, and Tyr1523 form the binding cage for H4K20me2 (13). In addition, a direct charge-charge interaction was identified between H4K16 and Glu1551 in 53BP1 that may be a method of regulation with respect to H4 binding proteins (13). Binding of 53BP1 to H4K20me2 facilitates the interaction of 53BP1 with the H2AK15ub epitope (14). Amino acids 1604-1631 (human 53BP1) comprise a ubiquitin-dependent recruitment (UDR) motif that interacts with an epitope formed by H2AK15ub and its surrounding residues on the H2A tail (14). The UDR, along with the Tudor domains facilitate the binding of the 53BP1 dimer to nucleosomes (14). Mutation of Ile1617, Leu1619, Asn1621, Leu1622, and Arg1627 to alanines prevented 53BP1 recruitment to DSB sites; the Ile1627Ala and Leu1619Ala mutations had the strongest impact on 53BP1 recruitment (14). Previous studies had determined the importance of Leu1619 and Leu1622 on 53BP1 recruitment (15). Mutation of all five sites impaired IR-induced foci formation (14).
Amino acids 1220-1601 of 53BP1 comprise a kinetochore-binding domain (KBD) (3;16). A nuclear localization signal (NLS; amino acids 1645-1703) and the KBD are sufficient to target 53BP1 to IR-induced foci (IRIF) (4). Deletion of the KBD resulted in loss of IRIF formation (17). Within the KBD, amino acids 1231–1270 are required for homo-oligomerization (15). The oligomerization domain is required for CSR and V(D)J (variable (V), diversity (D), and joining (J)) recombination, but is not required for chromatin binding (8). In cells expressing a mutant 53BP1 that lacked the oligomerization domain, telomeric fusions were reduced by 30-40% compared to the control due to the absence of cells with the longest multichromosome fusion products (18). Amino acids 1288-1409 are required for the interaction of 53BP1 with the breast cancer 1 early-onset (BRCA1) C-terminus (BRCT) domains of mediator of DNA damage checkpoint 1 (MDC1) (19).
53BP1 has two tandem BRCT domains at amino acids 1708-1969 (alternatively, amino acids 1723-1951, SMART) (8). BRCT domains are found in many proteins that function in DNA repair, DNA damage response signaling, and cell cycle checkpoints including BRCA1 and MDC1 (20;21). The BRCT domains of 53BP1 mediate protein-protein interactions, including that of 53BP1 with EXPAND1, a protein that promotes chromatin changes after DNA damage to facilitate repair (22;23), and that of 53BP1 with p53 (2;24;25). The crystal structure of the human BRCT domains (amino acids 1724-1974) bound to a heterodimer of the DNA binding region of p53 (amino acids 95-292) has been solved (Figure 8; PDB:1GZH) (24). The BRCT domains fold into a central four-stranded β-sheet with a pair of α-helices (α1 and α3) at one face and a single helix (α2) at the opposite face of the sheet; the β-sheet is the core of the structure (24). The α1 helix forms hydrophobic interactions with amino acids from β1 and β2, while the α2 helix interacts with β4 through hydrophobic interactions (24). Arg1813 and Asp1790 form hydrogen bonds to stabilize the α2/β4 interaction (24). The α1 and α3 helices form a two-helical bundle through hydrophobic interactions. A tryptophan in α3 interacts with residues from β1, β3 and β4. The inter-domain linker (amino acids 1851-1860) is a β-hairpin followed by an extended structure (amino acids 1861-1867). The DNA bound to a structural motif extending from helix α3 of the N-terminal BRCT and including the linker region between the two BRCT domains (24). The C-terminal BRCT domain extends away from the p53 interaction surface (24). Specific deletion of the BRCT domains (53BP1ΔBRCT), determined that the BRCT domains are dispensable for CSR, NHEJ, and protection of DNA ends from resection (8). However, a mutant that lacks the BRCT domains is deficient for the repair of DSBs in heterochromatin (26;27).
53BP1 undergoes several posttranslational modifications. Human 53BP1 has 32 phosphoinositide 3-kinase-like kinase (PIKK) Ser/Thr-Gln (S/TQ) consensus sites. Following IR, ten of the sites (Ser6, Ser25, Ser29, Ser166, Ser176/Ser178, Thr302, Ser452, Ser831, and Ser1219) are phosphorylated by a PIKK (e.g., ATM) (28-30). The S/TQ phosphorylation sites of 53BP1 are required for the accumulation of Rif1, a mediator of 53BP1 function in the suppression of end resection at deprotected telomeres (31-33). Callen et al. propose that a major Rif1 interaction motif is C-terminal to the eight S/TQ PTIP interaction sites (34). Ser25/29 are phosphorylation targets of ATM after DNA damage and are required to prevent DNA resection and support CSR (4;8). MDC1 regulates 53BP1 phosphorylation at Ser25/29 after DNA damage (35). Phosphorylation of 53BP1 at Ser25/29 is required for the correct phosphorylation of Chk2 and BRCA1 as well as for the subsequent checkpoint activation (35). However, mutation of the two sites to alanines did not abolish 53BP1 targeting (4). Phosphorylation of Ser25 is required for an interaction between 53BP1 and the BRCT domains of Pax transactivation domain-interacting protein (PTIP); disruption of the interaction leads to DNA-damage-sensitivity and reduced CHK2 phosphorylation (36). Ser1219 phosphorylation is essential for DNA-damage signaling and IR-induced G2/M cell cycle arrest (30). There are also 41 Ser/Thr-Pro (S/TP) cyclin-dependent kinase (CDK) consensus sites in 53BP1, although only four of the CDK consensus sites are known to be phosphorylated (29). The function of CDK-associated phosphorylation of 53BP1 is unknown. Lys1253 of 53BP1 is monoubiquitinated by the E3 ubiquitin ligase RAD18 in vitro, which retains 53BP1 near DSBs (37). Although initial recruitment of 53BP1 to chromatin is RAD18-independent, the retention of 53BP1 at DSBs requires RAD18-RAD6-associated modification of 53BP1 (37). RAD18 and 53BP1 physically interact in irradiated G1-phase cells, but not S- or G2/M-phase cells (37). After exposure to IR, most 53BP1 is polyubiquitinated and degraded by the ubiquitin-proteaseome system (38). Both the proteasome and cathepsin L (CTSL), a cysteine protease that functions in the endosomal/lysosomal degradation pathway, can induce 53BP1 degradation (39). A-type lamins upregulate CTSL activity, resulting in reduced stability and altered cellular distribution of 53BP1 (39). Overexpression of CTSL in fibroblasts results in the degradation of 53BP1 and subsequent defects in NHEJ (39).
53BP1 has a highly conserved glycine/arginine-rich region (GAR; RGRGRRGR; amino acids 1380-1386) (3;4). GARs are often found in RNA processing factors (4). The GAR of 53BP1 is methylated by protein arginine N-methyltranserase 1 (PRMT1), a modification that is proposed to mediate an association of 53BP1 with DNA (40;41).
The lentil mutation (A317S) is not within a defined domain in 53BP1. The aberrant splicing in lentil is predicted to code a 362-amino acid protein that would not contain domains that are characteristic of 53BP1 (i.e., the tandem Tudor domains and the tandem BRCT domains); the expression, function, and localization of the 53BP1lentil protein have not been examined.
53BP1 was detected in all human tissues tested by Northern blot, except for lung and liver (2). Bothmer et al. detected 53BP1 at chromatin in the absence of DNA damage (8). Iwabuchi et al. determined that in COS-1 cells transfected with HA-tagged 53BP1, the construct localized both in the cytoplasm and nucleus in some cells and only in the nucleus in others (42). The transfected COS-1 cells display two nuclear patterns for 53BP1: homogenous and dot staining (42). 53BP1 exhibits a differential localization pattern through the phases of the cell cycle. During mitosis in HeLa cells, GFP-tagged mouse 53BP1 localized to the kinetochore (16). In the G1 phase of the cell cycle, 53BP1 was localized in a diffuse nuclear pattern as well as in large nuclear “dots” (17). In the S-phase, 53BP1 was localized in a discrete, punctate pattern (17). In the G2 phase, 53BP1 localization was similar to that observed in S-phase cells, but there were fewer loci (17). In interphase, 53BP1 did not colocalize with kintechores (16). During mouse embryonic development, 53BP1 was detected only from the 2-cell stage onwards on chromatin and was absent from mitotic chromosomes (43). In zygotes after fertilization (PN0), 53BP1 was localized only in the cytoplasm and was not associated to the anaphase chromosomes on the female pronucleus or the forming male pronucleus (43). At pronuclear stage PN4, 53BP1 was predominantly cytoplasmic with some localization to the nucleus and pronuclei (43). At the 2-cell stage, 53BP1 exhibited some cytoplasmic localization, but the protein was enriched in the nucleus (43). At the 8-cell stage, 53BP1 exhibited more pronounced enrichment of 53BP1, but some 53BP1 was also detected in the cytoplasm (43). At the morula stage, 53BP1 was excluded from the nucleus and was predominantly cytoplasmic (43). At the blastocyst stage, 53BP1 did not localize to the inner cell mass cells, but 53BP1 was enriched in trophectoderm cells; it was not localized to the nucleus (43). However some cells next to the blastocyst cavity exhibited cytoplasmic and nuclear 53BP1 localization, indicating that changes of cytoplasmic to nuclear 53BP1 localization may be temporally regulated (43).
53BP1 has several functions including facilitating DNA damage signaling, telomere fusions, NHEJ of DNA double strand break (DSBs) in CSR, transducing ATM-dependent cell cycle checkpoints (intra-S and G2/M), accumulation of p53, phosphorylation of several ATM substrates (e.g., Chk2 and BRCA1) in response to IR, and tumor suppression (7;30;44-49). Several of these functions are described in more detail, below.
Several factors are involved in DNA damage response (DDR) signaling including DNA damage sensors, mediators, transducers, and effectors [reviewed in (12)]. The MRN [MRE11 (meiotic recombination 11)–Rad50–NBS1 (Nijmegen breakage syndrome 1)] complex and the PIKKs ATM, ATM and Rad3-related (ATR) and DNA-PK (DNA-dependent protein kinase; see the record for clover) are involved in early DNA DSB-induced signaling [Figure 9; reviewed in (12)]. Mediator/adaptor proteins such as MDC1, BRCA1, PTIP, and 53BP1 facilitate signaling between sensors and transducers to enhance DDR signaling. 53BP1 tethers activated ATM and other repair factors at the site of DSBs (26;27). 53BP1 is required efficient autophosphorylation of ATM at Ser1981 as well as ATM activation in some cell lines (50;51). 53BP1-mediated regulation of ATM-dependent phosphorylation of substrates in response to IR indicates that 53BP1 is a DNA damage checkpoint protein that facilitates ATM phosphorylation events (47). In irradiated U2OS cells, ATM coprecipitated with 53BP1, but not in non-irradiated cells, indicating that the interaction of 53BP1 and ATM is DNA damage-specific (47). DiTullio et al. propose that 53BP1 may function upstream of ATM to activate ATM in response to DSBs, and/or that 53BP1 functions as a scaffold to recruite ATM substrates to ATM at DSBs (47). ATM suppresses end resection in 53BP1-deficient cells in G1, but not in S/G2 phase of the cell cycle (52-54).
The recruitment of 53BP1 to DSBs is essential for DDR signaling. An IR-induced DSB induces the phosphorylation of H2AX at Ser139 by PIKKs (ATM/ATR/DNA-PKcs) to form γ-H2AX. 53BP1 subsequently relocates to nuclear foci that colocalize at DSB sites with γ-H2AX (4;7;55), the MRN complex, and BRCA1 (11). The γ-H2AX is not required for initial recruitment of 53BP1 to the foci (56), but is required for sustained retention of these foci (28;48). MDC1 also binds to γ-H2AX via its BRCT domains (57) and the E3 ligases RNF8 and RNF168 are recruited. RNF8 and RNF168 ubiquitinate H2A and/or H2AX (18;58) and mediate the degradation of chromatin proteins (e.g., JMJD2A and L3MBTL1) and/or proteins that bind to H4K20me2 that may compete with 53BP1 (59;60). Focal recruitment of 53BP1 also requires Tip60 histone acetyltransferase activity, which is proposed to facilitate the formation of a more open chromatin structure through histone acetylation (61). The PIKKs transduce the DNA damage signal to transducer kinases such as checkpoint kinase 1 (CHK1) and CHK2, factors that are involved in signal transduction events that target additional DDR components as well as in amplifying the DDR signal. The sensor and transducer kinases phosphorylate downstream effector molecules such as p53 to initiate a biological response.
53BP1 has a role in both ATR-Chk1- and ATM-Chk2-associated signaling (62). Although 53BP1 physically interacts with Chk2, the interaction was decreased after IR, resulting in decreased phosphorylation of Chk2, indicating that 53BP1 regulates Chk2 activity [(44); reviewed in (63)]. In addition, siRNA-mediated knockdown of 53BP1 resulted in a ~50% decrease in phosphorylated Chk1 levels one hour after IR exposure (62).
The function of 53BP1 in p53-associated activity is conflicting. Iwabuchi et al. proposed that 53BP1 enhances p53-mediated transcription of reporter genes by acting as a transcriptional co-activator of p53 (42). Ward et al. found that without 53BP1 expression, the transactivation activity of p53 was increased, indicating that 53BP1 may negatively regulate p53 function (64). They speculate that differences in earlier studies showing that 53BP1 facilitates p53-mediated transcription are due to artificial 53BP1 overexpression (64). 53BP1 is required for p53 accumulation in response to IR (44), but it is not required for stabilization of p53 or for the IR-induced expression of Mdm2 and p21, downstream p53 factors (64).
53BP1 and the type of DSB DNA repair
Homologous recombination (HR) and nonhomologous end-joining (NHEJ) occur upon recognition of a DNA DSB (Figure 10). HR is a relatively error-free mechanism for DSB repair that relies on the homologous region on the sister chromatid as a template for DNA synthesis (65). HR is limited to replicating cells (including early embryonic developmental stages) and can be observed only after DNA replication in the S and G2 phases (66). NHEJ is a rapid repair mechanism that simply ligates broken DNA ends after minimal or no processing. NHEJ occurs in all phases of the cell cycle and is thought to be the primary DNA repair pathway in mammalian cells (67). NHEJ is prone to generating mutations at the point of ligation, and may result in inversions or translocations if the joined strands were not originally contiguous. For a detailed description of NHEJ, please the record for clover.
53BP1 functions in the choice of DSB repair. During G1, 53BP1 promotes classic (C)-NHEJ by tethering DSBs together and by protecting the ends from exonuclease processing and subsequent resection of DSBs (52;68). 53BP1 prevents 5’ end resection after DSBs and is critical for CSR in G1, but can lead to genomic instability in the S-phase (34). Exonucleases can generate large deletions that contain long 3’ single-stranded tails that promote homologous recombination (HR) and alternative (A)-NHEJ [(52;53); reviewed in (69)]. A-NHEJ is a repair pathway that occurs when the core C-NHEJ factors (Ku70, Ku80, XRCC4, or Lig4) are absent and generates microhomology-mediated signatures at repair junctions (70); the A-NHEJ pathway is mostly active when DNA ends are poorly protected, such as in the loss of 53BP1 (52). Single-strand overhangs are prominent on telomeres in Trp53bp1-/- cells (46). The loss of 53BP1 results in increased intra-switch region deletions and chromosome translocations, processes mediated primarily by A-NHEJ (71;72). The siRNA-mediated depletion of 53BP1 stimulated HR in U2OS cells (73). In mouse ES cells, siRNA-mediated depletion of 53BP1 led to only a slight increase in HR. 53BP1 does not contribute to NHEJ in V(D)J recombination (45;46;49). Dimitrova et al. propose that the distinction between 53BP1-dependent and –independent NHEJ reactions is due to the distance between the DNA ends involved (46). During NHEJ, 53BP1 is required for long-range joining of distant DNA breaks (68;74). The two ends generated by RAG1/2 or chromosome-internal DNA damage are close in proximity, while the DNA ends generated by activation-induced cytidine deaminase (AID) in CSR as well as the NHEJ-processed dysfunctional telomeres in G1 are far apart (75).
53BP1 is required for HR at euchromatin regions and promotes HR specifically at heterochromatin (HC)-DSBs in G2 cells (76). In G2 phase cells 53BP1 has both an inhibitory and pro-HR role (76). The 53BP1 inhibitory role is relieved by BRCA1-dependent repositioning of 53BP1 to the periphery of γ-H2AX foci (76). In the absence of BRCA1, HR does not proceed due to the inhibitory role of 53BP1 (76). 53BP1 is dispensable for HR in S-phase cells as well as in G2 cells after depletion of DNA-PK (76). BRCA1 is structurally similar to 53BP1 at its C-terminus and also functions in ATM-dependent DDR (27;62). BRCA1 and 53BP1 have reciprocal roles in DSB repair: BRCA1 is required for HR, while 53BP1 is required for NHEJ. In S/G2-phase cells, BRCA1 facilitates the removal of 53BP1 from DSBs allowing from resection and DSB repair by HR (53;77;78). In Brca1-deficient mice, the embryonic lethality, tumor predisposition and HR defect (chromosomal abnormalities) phenotypes are rescued by the deletion of Trp53bp1 (53;77;79). In addition, 53BP1 was required for the cellular senescence and apoptosis caused by loss of Brca1 expression (79). The phenotypes associated with Brca1 deficiency, are proposed to be due to an inability to counteract 53BP1-dependent toxic NHEJ in S/G2 (31). Bunting et al. propose that the binding of 53BP1 to chromatid breaks in Brca1-deficient (Brca1-/-) cells prevents HR by partially blocking ATM-dependent resection at the break site, a role that is necessary for HR (53). The loss of 53BP1 (53BP1-/-) in the Brca1-/- cells suppresses the HR defect (53;77). The Brca1-/- /53BP1-/- cells exhibited increased levels of DSBs, intact ATM-Chk2-p53 signaling and IR-induced apoptosis (79). Brca1-/- /53BP1-/- cells have restored HR and genomic stability as well as a resistance to poly(ADP)ribose polymerase inhibitors (PARPi) (13;80). PARP functions in organismal development and DSB repair independent of both H2AX and 53BP1 (81). In Brca1-/- cells, 53BP1 enhances aberrant NHEJ events that create lethal radial chromosomes, due to mis-rejoined DSBs, in response to PARPi (53;82;83). However, upon depletion of 53BP1, the formation of the PARPi-associated lethal radial chromosomes in Brca1-/- cells is prevented.
IR-induced cell cycle checkpoints
53BP1 functions in both IR-induced intra-S and the G2/M cell cycle checkpoints in human and mouse cells (44); a role in the G1/S phase checkpoint has not been detected. 53BP1 recruits substrates to the ATM and ATR checkpoint kinases (44). Loss of 53BP1 expression abrogates the ATM-dependent checkpoint response and G2/M cell cycle arrest upon accumulation of IR-induced DNA breaks (53;77). In addition, loss of 53BP1 expression results in partial intra-S phase checkpoint defects following IR treatment (28;44). As a result, there was inappropriate progression into mitosis (35). Minter-Dykhouse et al. propose that 53BP1 functions in the same molecular pathway downstream of ATM as MDC1 (35).
V(D)J recombination affects the variable domain of immunoglobulin and T cell receptor (TCR) genes. For a detailed description of V(D)J recombination, please see the record for clover. RAG1/2-induced DNA lesions in antigen receptor loci result in the recruitment of γ-H2AX, NBS1 and 53BP1 (84;85). In v-abl transformed B cells, 53BP1 deficiency does not appreciably affect V(D)J recombination (7). However, in XLF (X-ray repair cross-complementing 4-like factor)-deficient lymphocytes, 53BP1 is required for end ligation during V(D)J recombination (7;86). In Trp53bp1 knockout (Trp53bp1-/-) mice, CSR in the IgH locus was reduced (45;49). In Trp53bp1-/- mice, V(D)J recombination in the TCRα and TCRδ loci were functional, but fewer precursor thymic T cells were observed indicating that loss of Trp53bp1 expression resulted in defective T cell development (68). Joining of the closely spaced D and J segments was not reduced at the TCRδ locus, but complete V(D)J rearrangements over a longer distance were affected by the loss of Trp53bp1 expression (68).
Class switch recombination
CSR facilities the production of antibodies of different isotypes in mature B cells during a humoral immune response [Figure 11; (45;49)]. CSR is a recombination reaction that occurs between paired DSBs in immunoglobulin heavy chain (Igh) switch regions (S-regions) that flank Igh constant regions (87). The S-regions contain a repetitive sequence that can serve as a substrate for proximal microhomology-mediated intra-switch repair by C-NHEJ (52;70). During CSR, AID converts cytosines into uracils at the S-region (88). The excision of uracils from both DNA strands results in staggered DNA breaks at donor and acceptor switch regions (88). The IgH locus lesions are detected as DSBs by the MRN complex, which leads to phosphorylation of H2AX, the recruitment of 53BP1 to the IgH locus, and eventual end joining by C- or A-NHEJ (74;84;87). During CSR, 53BP1 facilitates synapsis as well as protects DNA ends from resection (8;88). 53BP1 is required for long-range intra-chromosomal end-joining during CSR and V(D)J recombination (46;49;68;71). ATM-dependent phosphorylation of 53BP1 is essential for the recruitment of Rif1 to DSB sites (31-33). It is unknown whether Rif1 directly binds to 53BP1, or through interactions with effector molecules that contain BRCT domains (34). Rif1 suppresses 5’ end resection at IR-induced DSBs and during CSR in B lymphocytes (31;33;89). Rif1 is not required for 53BP1-associated increased in dysfunctional telomere mobility (33). 53BP1 deficiency results in an almost complete loss of long range CSR and a concomitant increase in the frequency of short-range intra switch recombination (71). Without 53BP1, CSR in lymphocytes is impaired and broken DNA is resected, producing single-stranded DNA that serves as a substrate for repair by A-NHEJ (45;49;52;53;68).
In mice, 53BP1 has overlapping tumor suppression function with XLF (7) and MDC1 (35). In the context of p53 deficiency, impaired 53BP1 function alters cancer susceptibility by accelerating the rate of tumorigenesis (90). In Trp53bp1-/-/p53-/-thymic lymphomas, tumorigenesis proceeds through aneuploidy and/or clonal translocations (64;90). Downregulation of 53BP1 expression in BRCA-mutant breast tumors promoted the viability of the cancer cells (53;77).
Dysregulation of TRP53BP1 expression is associated with several human conditions. TRP53BP1 expression in BRCA1-associated breast cancers (53;77), lymphomas, and solid tumors is reduced (77;91-93). Low levels of TRP53BP1 are correlated with an aggressive form of the disease, correlating with increased metastases and decreased survival [reviewed in (94)]. There is a correlation between loss of TRP53BP1 expression and the triple negative (lacks expression of the estrogen and progesterone receptors as well as the human epidermal growth factor receptor 2 (HER2)) phenotype [reviewed in (94)]. 90% of TRP53BP1-/- tumors are also triple negative; 43% of triple negative tumors are also TRP53BP1-/- [reviewed in (94)]. 53BP1 deficiency and the deregulation of AID, leads to increased DSB formation, resulting in B cell lymphoma (95). Deep sequencing of TRP53BP1-/- cancer cells determined that they exhibited increased DNA end resection compared to wild-type cells (95). Patients with RIDDLE syndrome (OMIM: #611943) lack the ability to recruit 53BP1 to the sites of DNA DSBs (96). Sequencing of the TRP53BP1 gene, and other genes that regulate IR-induced 53BP1 foci formation, did not detect any mutations, indicating that a protein upstream of 53BP1 is impaired (96). Patients with RIDDLE syndrome exhibit immunodeficiency, increased radiosensitivity, mild motor control, learning difficulties, facial dysmorphism, and short stature. Cells from RIDDLE patients are hypersensitive to IR and exhibit cell cycle checkpoint abnormalities as well as impaired end-joining in the recombined switch regions (96). In a patient with RIDDLE syndrome, the IgG and IgM levels were below normal limits by one year of age (96).
Trp53bp1 mouse models
Two Trp53bp1 mouse models have been developed. One is a gene-targeted mutation (Trp53bp1-/-; Trp53bp1tm1Jc, MGI:2654201) (97), while the other is a random retroviral insertion within intron 13 that prevented exon 13 to properly splice to exon 14, disrupting the Trp53bp1 gene and producing a 1,226 amino acid truncated (tr) 53BP1 protein that does not include the NLS, KBD, and the BRCT domains (m53BP1tr/tr; Trp53bp1Gt(OST94324)Lex, MGI:2661096) (17). The m53BP1tr protein was unable to form foci in response to DNA damage and was absent from the nucleus (17). Fibroblasts from the Trp53bp1-/- mice showed no spontaneous chromosomal breaks, however, there was a tendency toward aneuploidy and/or tetraploidy indicating a possible defect in chromosome segregation (97). The m53BP1tr/tr mice also exhibited chromosomal aberrations (17). MEFs from both Trp53bp1-/- and m53BP1tr/tr embryos exhibited reduced proliferation compared to controls (97). Both models are viable, but exhibit growth retardation and increased cellular sensitivity to IR (17;97). The m53BP1tr/tr mice were fertile, but produced smaller litters than wild-type animals (17). After IR, Trp53bp1-/- cells arrested in G2 and exhibited a delayed exit from the G2/M phase; the percentage of mitotic cells 24 hours after IR was lower than wild-type cells (97). Both Trp53bp1 mutant mouse models exhibited lethality 9-15 days after exposure to 7-8 Gy of IR; most wild-type mice were viable for at least 2 months after irradiation (17;97). Necropsy of the Trp53bp1-/- mice revealed radiation-induced intestinal bleeding and bone marrow failure as the cause of death (97). Treatment of the m53BP1tr/tr mice with lower doses of IR (1.5 Gy) did not cause lethality (17). The Trp53bp1 mouse models exhibit immune deficiencies including defects in T cell maturation (17;97). The levels of CD4 T cells, γ–δ T cells, and B cells were all reduced in the Trp53bp1-/- mice with a concomitant increase in the percentage of CD4-CD8- progenitors and apoptosis (68;97). In addition, the Trp53bp1-/- thymocytes exhibited an increased number of aberrant cells (either lost Cα (2 TCRVα, 1 TCRCα signal) or both Vα and Cα from one allele (1 TCRVα, 1 TCRCα)) (68). Bone marrow pro-B, pre-B, myeloid, and erthyroid progenitor populations were normal in the m53BP1tr/tr mice (17;49). However, the spleens from the m53BP1tr/tr mice were deficient in mature B cells (IgMloIgDhi) (17). IgM levels in the Trp53bp1-/- mice were similar to those in wild-type mice, indicating that B cell activation to mediate IgM secretion is not affected upon loss of 53BP1, however, the levels of all IgG subclasses and IgA were decreased (49). CD4 and CD8 T cell populations were similar between m53BP1tr/tr and wild-type mice, but the progression out of the DNIII stage in development, when β-gene rearrangement occurs, was impaired in the m53BP1tr/tr mice (17). Thymus size in the m53BP1tr/tr mice was smaller and had fewer cells than wild-type mice; the lymphoid organ architecture was normal (17). Trp53bp1-/- mice exhibit premature postnatal lethality between 4 to 7 months due to thymic lymphoma (97). In older Trp53bp1-/- mice, pulmonary carcinoma was also prevalent (64). Heterozygotes exhibited accelerated tumorigenesis (e.g., lymphomas, sarcomas, and carcinomas) in a p53-deficient background (64). Heterozygotes in a p53+/+genetic background also exhibited a higher predisposition to cancer than wild-type mice (64). Cancerous phenotypes in the m53BP1tr/tr mice were not observed (17).
IgD and IgM are the alternatively spliced Igh product made by mature B lymphocytes; IgM and IgD are receptors for antigen on naïve mature B cells (98). IgD is coexpressed with IgM when the cells mature into follicular or marginal zone B cells (98). After exposure to antigens, B cells undergo isotype switching, irreversibly losing IgM and IgD and switching to express the same variable domaine linked to IgG, IgA, or IgE constant region domains. Trp53bp1-/- mice exhibit reduced CSR at the IgH locus [Figure 11; (45;49)] and the spleens from the m53BP1tr/tr mice were deficient in mature B cells (IgMloIgDhi) (17). During CSR, 53BP1 facilitates synapsis as well as protects DNA ends from resection (8;8). In addition, 53BP1 is required for long-range intra-chromosomal end-joining during CSR (46;49;68;74). The levels of IgD on circulating B cells is decreased in lentil, but is difficult to reconcile with an effect on CSR because no such defect is observed in the spleen. Age-dependency of the low IgD expression is also a peculiar feature of the mutation; notable as well is the observation that in bone marrow transplantation, extrahematopoietic tissues bearing the mutation exert control over the level of IgD expression.
In the lentil mice, both A-NHEJ and HR pathways contributed to the increased IgD class-swtich recombination. CSR to IgD requires an intact microbiome and Toll-like receptor signaling, and is confined to B cells of mucosa-associated lymphoid tissues (1).
lentil(F):5'- AATCCCACGCTTTCCTAGATGCAC -3'
lentil(R):5'- AGTCCTCAAGTTTCTGTTGCTGCTG -3'
lentil_seq(F):5'- GCTGACAAGTAAACACTCTCTG -3'
lentil_seq(R):5'- TGTTGCTGCTGTGGAAACAAAG -3'
Lentil genotyping is performed by amplifying the region containing the mutation using PCR, followed by sequencing of the amplified region to detect the single nucleotide transition.
Lentil(F): 5’- AATCCCACGCTTTCCTAGATGCAC-3’
Lentil(R): 5’- AGTCCTCAAGTTTCTGTTGCTGCTG-3’
Lentil_seq(F): 5’- GCTGACAAGTAAACACTCTCTG-3’
Lentil_seq(F): 5’- TGTTGCTGCTGTGGAAACAAAG-3’
1) 94°C 2:00
2) 94°C 0:30
3) 55°C 0:30
4) 72°C 1:00
5) repeat steps (2-4) 29X
6) 72°C 7:00
7) 4°C ∞
The following sequence of 403 nucleotides is amplified (Chr.2: 121251613-121252015, GRCm38):
1 aatcccacgc tttcctagat gcactcctac gtcacctcaa cttccaaaag ggtgaaagct
61 acacagaacg ctgacaagta aacactctct gacagccctc attactgact ggctagagat
121 atattttcct tctatatcat tagctattcc aaatcatagc tatttttaaa agtgcttttt
181 aacagtagcc tcagaactaa aataaaaatg tagaacaagt gagaagagga gctgtggagc
241 aatcagcctc cctacctgtt ttactactct ggtcaaacaa gtcctcctgg gttgaggaaa
301 cctcaggctc tgatgacggc tgaacctgcg gcccctcttc cagcagctcc cgggcaggta
361 cctgttcctt tgtttccaca gcagcaacag aaacttgagg act
Primer binding sites are underlined and the sequencing primer is highlighted; the mutated nucleotide is shown in red text (C>A, Chr. + strand; G>T, sense strand).
1. Choi, J. H., Wang, K. W., Zhang, D., Zhan, X., Wang, T., Bu, C. H., Behrendt, C. L., Zeng, M., Wang, Y., Misawa, T., Li, X., Tang, M., Zhan, X., Scott, L., Hildebrand, S., Murray, A. R., Moresco, E. M., Hooper, L. V., and Beutler, B. (2017) IgD Class Switching is Initiated by Microbiota and Limited to Mucosa-Associated Lymphoid Tissue in Mice. Proc Natl Acad Sci U S A. 114, E1196-E1204.
2. Iwabuchi, K., Bartel, P. L., Li, B., Marraccino, R., and Fields, S. (1994) Two Cellular Proteins that Bind to Wild-Type but Not Mutant p53. Proc Natl Acad Sci U S A. 91, 6098-6102.
3. Charier, G., Couprie, J., Alpha-Bazin, B., Meyer, V., Quemeneur, E., Guerois, R., Callebaut, I., Gilquin, B., and Zinn-Justin, S. (2004) The Tudor Tandem of 53BP1: A New Structural Motif Involved in DNA and RG-Rich Peptide Binding. Structure. 12, 1551-1562.
4. Pryde, F., Khalili, S., Robertson, K., Selfridge, J., Ritchie, A. M., Melton, D. W., Jullien, D., and Adachi, Y. (2005) 53BP1 Exchanges Slowly at the Sites of DNA Damage and Appears to Require RNA for its Association with Chromatin. J Cell Sci. 118, 2043-2055.
5. Iwabuchi, K., Basu, B. P., Kysela, B., Kurihara, T., Shibata, M., Guan, D., Cao, Y., Hamada, T., Imamura, K., Jeggo, P. A., Date, T., and Doherty, A. J. (2003) Potential Role for 53BP1 in DNA End-Joining Repair through Direct Interaction with DNA. J Biol Chem. 278, 36487-36495.
6. Huyen, Y., Zgheib, O., Ditullio, R. A.,Jr, Gorgoulis, V. G., Zacharatos, P., Petty, T. J., Sheston, E. A., Mellert, H. S., Stavridi, E. S., and Halazonetis, T. D. (2004) Methylated Lysine 79 of Histone H3 Targets 53BP1 to DNA Double-Strand Breaks. Nature. 432, 406-411.
7. Liu, X., Jiang, W., Dubois, R. L., Yamamoto, K., Wolner, Z., and Zha, S. (2012) Overlapping Functions between XLF Repair Protein and 53BP1 DNA Damage Response Factor in End Joining and Lymphocyte Development. Proc Natl Acad Sci U S A. 109, 3903-3908.
8. Bothmer, A., Robbiani, D. F., Di Virgilio, M., Bunting, S. F., Klein, I. A., Feldhahn, N., Barlow, J., Chen, H. T., Bosque, D., Callen, E., Nussenzweig, A., and Nussenzweig, M. C. (2011) Regulation of DNA End Joining, Resection, and Immunoglobulin Class Switch Recombination by 53BP1. Mol Cell. 42, 319-329.
9. Ponting, C. P. (1997) Tudor Domains in Proteins that Interact with RNA. Trends Biochem Sci. 22, 51-52.
10. Botuyan, M. V., Lee, J., Ward, I. M., Kim, J. E., Thompson, J. R., Chen, J., and Mer, G. (2006) Structural Basis for the Methylation State-Specific Recognition of Histone H4-K20 by 53BP1 and Crb2 in DNA Repair. Cell. 127, 1361-1373.
11. Schultz, L. B., Chehab, N. H., Malikzay, A., and Halazonetis, T. D. (2000) P53 Binding Protein 1 (53BP1) is an Early Participant in the Cellular Response to DNA Double-Strand Breaks. J Cell Biol. 151, 1381-1390.
12. FitzGerald, J. E., Grenon, M., and Lowndes, N. F. (2009) 53BP1: Function and Mechanisms of Focal Recruitment. Biochem Soc Trans. 37, 897-904.
13. Tang, J., Cho, N. W., Cui, G., Manion, E. M., Shanbhag, N. M., Botuyan, M. V., Mer, G., and Greenberg, R. A. (2013) Acetylation Limits 53BP1 Association with Damaged Chromatin to Promote Homologous Recombination. Nat Struct Mol Biol. 20, 317-325.
14. Fradet-Turcotte, A., Canny, M. D., Escribano-Diaz, C., Orthwein, A., Leung, C. C., Huang, H., Landry, M. C., Kitevski-LeBlanc, J., Noordermeer, S. M., Sicheri, F., and Durocher, D. (2013) 53BP1 is a Reader of the DNA-Damage-Induced H2A Lys 15 Ubiquitin Mark. Nature. 499, 50-54.
15. Zgheib, O., Pataky, K., Brugger, J., and Halazonetis, T. D. (2009) An Oligomerized 53BP1 Tudor Domain Suffices for Recognition of DNA Double-Strand Breaks. Mol Cell Biol. 29, 1050-1058.
16. Jullien, D., Vagnarelli, P., Earnshaw, W. C., and Adachi, Y. (2002) Kinetochore Localisation of the DNA Damage Response Component 53BP1 during Mitosis. J Cell Sci. 115, 71-79.
17. Morales, J. C., Xia, Z., Lu, T., Aldrich, M. B., Wang, B., Rosales, C., Kellems, R. E., Hittelman, W. N., Elledge, S. J., and Carpenter, P. B. (2003) Role for the BRCA1 C-Terminal Repeats (BRCT) Protein 53BP1 in Maintaining Genomic Stability. J Biol Chem. 278, 14971-14977.
18. Lottersberger, F., Bothmer, A., Robbiani, D. F., Nussenzweig, M. C., and de Lange, T. (2013) Role of 53BP1 Oligomerization in Regulating Double-Strand Break Repair. Proc Natl Acad Sci U S A. 110, 2146-2151.
19. Eliezer, Y., Argaman, L., Rhie, A., Doherty, A. J., and Goldberg, M. (2009) The Direct Interaction between 53BP1 and MDC1 is Required for the Recruitment of 53BP1 to Sites of Damage. J Biol Chem. 284, 426-435.
20. Bork, P., Hofmann, K., Bucher, P., Neuwald, A. F., Altschul, S. F., and Koonin, E. V. (1997) A Superfamily of Conserved Domains in DNA Damage-Responsive Cell Cycle Checkpoint Proteins. FASEB J. 11, 68-76.
21. Callebaut, I., and Mornon, J. P. (1997) From BRCA1 to RAP1: A Widespread BRCT Module Closely Associated with DNA Repair. FEBS Lett. 400, 25-30.
22. Huen, M. S., Huang, J., Leung, J. W., Sy, S. M., Leung, K. M., Ching, Y. P., Tsao, S. W., and Chen, J. (2010) Regulation of Chromatin Architecture by the PWWP Domain-Containing DNA Damage-Responsive Factor EXPAND1/MUM1. Mol Cell. 37, 854-864.
23. Ward, I., Kim, J. E., Minn, K., Chini, C. C., Mer, G., and Chen, J. (2006) The Tandem BRCT Domain of 53BP1 is Not Required for its Repair Function. J Biol Chem. 281, 38472-38477.
24. Derbyshire, D. J., Basu, B. P., Serpell, L. C., Joo, W. S., Date, T., Iwabuchi, K., and Doherty, A. J. (2002) Crystal Structure of Human 53BP1 BRCT Domains Bound to p53 Tumour Suppressor. EMBO J. 21, 3863-3872.
25. Joo, W. S., Jeffrey, P. D., Cantor, S. B., Finnin, M. S., Livingston, D. M., and Pavletich, N. P. (2002) Structure of the 53BP1 BRCT Region Bound to p53 and its Comparison to the Brca1 BRCT Structure. Genes Dev. 16, 583-593.
26. Noon, A. T., Shibata, A., Rief, N., Lobrich, M., Stewart, G. S., Jeggo, P. A., and Goodarzi, A. A. (2010) 53BP1-Dependent Robust Localized KAP-1 Phosphorylation is Essential for Heterochromatic DNA Double-Strand Break Repair. Nat Cell Biol. 12, 177-184.
27. Lee, J. H., Goodarzi, A. A., Jeggo, P. A., and Paull, T. T. (2010) 53BP1 Promotes ATM Activity through Direct Interactions with the MRN Complex. EMBO J. 29, 574-585.
28. Ward, I. M., Minn, K., Jorda, K. G., and Chen, J. (2003) Accumulation of Checkpoint Protein 53BP1 at DNA Breaks Involves its Binding to Phosphorylated Histone H2AX. J Biol Chem. 278, 19579-19582.
29. Jowsey, P., Morrice, N. A., Hastie, C. J., McLauchlan, H., Toth, R., and Rouse, J. (2007) Characterisation of the Sites of DNA Damage-Induced 53BP1 Phosphorylation Catalysed by ATM and ATR. DNA Repair (Amst). 6, 1536-1544.
30. Lee, H., Kwak, H. J., Cho, I. T., Park, S. H., and Lee, C. H. (2009) S1219 Residue of 53BP1 is Phosphorylated by ATM Kinase upon DNA Damage and Required for Proper Execution of DNA Damage Response. Biochem Biophys Res Commun. 378, 32-36.
31. Chapman, J. R., Barral, P., Vannier, J. B., Borel, V., Steger, M., Tomas-Loba, A., Sartori, A. A., Adams, I. R., Batista, F. D., and Boulton, S. J. (2013) RIF1 is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection. Mol Cell. 49, 858-871.
32. Escribano-Diaz, C., Orthwein, A., Fradet-Turcotte, A., Xing, M., Young, J. T., Tkac, J., Cook, M. A., Rosebrock, A. P., Munro, M., Canny, M. D., Xu, D., and Durocher, D. (2013) A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice. Mol Cell. 49, 872-883.
33. Zimmermann, M., Lottersberger, F., Buonomo, S. B., Sfeir, A., and de Lange, T. (2013) 53BP1 Regulates DSB Repair using Rif1 to Control 5' End Resection. Science. 339, 700-704.
34. Callen, E., Di Virgilio, M., Kruhlak, M. J., Nieto-Soler, M., Wong, N., Chen, H. T., Faryabi, R. B., Polato, F., Santos, M., Starnes, L. M., Wesemann, D. R., Lee, J. E., Tubbs, A., Sleckman, B. P., Daniel, J. A., Ge, K., Alt, F. W., Fernandez-Capetillo, O., Nussenzweig, M. C., and Nussenzweig, A. (2013) 53BP1 Mediates Productive and Mutagenic DNA Repair through Distinct Phosphoprotein Interactions. Cell. 153, 1266-1280.
35. Minter-Dykhouse, K., Ward, I., Huen, M. S., Chen, J., and Lou, Z. (2008) Distinct Versus Overlapping Functions of MDC1 and 53BP1 in DNA Damage Response and Tumorigenesis. J Cell Biol. 181, 727-735.
36. Munoz, I. M., Jowsey, P. A., Toth, R., and Rouse, J. (2007) Phospho-Epitope Binding by the BRCT Domains of hPTIP Controls Multiple Aspects of the Cellular Response to DNA Damage. Nucleic Acids Res. 35, 5312-5322.
37. Watanabe, K., Iwabuchi, K., Sun, J., Tsuji, Y., Tani, T., Tokunaga, K., Date, T., Hashimoto, M., Yamaizumi, M., and Tateishi, S. (2009) RAD18 Promotes DNA Double-Strand Break Repair during G1 Phase through Chromatin Retention of 53BP1. Nucleic Acids Res. 37, 2176-2193.
38. Zhang, D., Zaugg, K., Mak, T. W., and Elledge, S. J. (2006) A Role for the Deubiquitinating Enzyme USP28 in Control of the DNA-Damage Response. Cell. 126, 529-542.
39. Gonzalez-Suarez, I., Redwood, A. B., Grotsky, D. A., Neumann, M. A., Cheng, E. H., Stewart, C. L., Dusso, A., and Gonzalo, S. (2011) A New Pathway that Regulates 53BP1 Stability Implicates Cathepsin L and Vitamin D in DNA Repair. EMBO J. 30, 3383-3396.
40. Boisvert, F. M., Rhie, A., Richard, S., and Doherty, A. J. (2005) The GAR Motif of 53BP1 is Arginine Methylated by PRMT1 and is Necessary for 53BP1 DNA Binding Activity. Cell Cycle. 4, 1834-1841.
41. Adams, M. M., Wang, B., Xia, Z., Morales, J. C., Lu, X., Donehower, L. A., Bochar, D. A., Elledge, S. J., and Carpenter, P. B. (2005) 53BP1 Oligomerization is Independent of its Methylation by PRMT1. Cell Cycle. 4, 1854-1861.
42. Iwabuchi, K., Li, B., Massa, H. F., Trask, B. J., Date, T., and Fields, S. (1998) Stimulation of p53-Mediated Transcriptional Activation by the p53-Binding Proteins, 53BP1 and 53BP2. J Biol Chem. 273, 26061-26068.
43. Ziegler-Birling, C., Helmrich, A., Tora, L., and Torres-Padilla, M. E. (2009) Distribution of p53 Binding Protein 1 (53BP1) and Phosphorylated H2A.X during Mouse Preimplantation Development in the Absence of DNA Damage. Int J Dev Biol. 53, 1003-1011.
44. Wang, B., Matsuoka, S., Carpenter, P. B., and Elledge, S. J. (2002) 53BP1, a Mediator of the DNA Damage Checkpoint. Science. 298, 1435-1438.
45. Ward, I. M., Reina-San-Martin, B., Olaru, A., Minn, K., Tamada, K., Lau, J. S., Cascalho, M., Chen, L., Nussenzweig, A., Livak, F., Nussenzweig, M. C., and Chen, J. (2004) 53BP1 is Required for Class Switch Recombination. J Cell Biol. 165, 459-464.
46. Dimitrova, N., Chen, Y. C., Spector, D. L., and de Lange, T. (2008) 53BP1 Promotes Non-Homologous End Joining of Telomeres by Increasing Chromatin Mobility. Nature. 456, 524-528.
47. DiTullio, R. A.,Jr, Mochan, T. A., Venere, M., Bartkova, J., Sehested, M., Bartek, J., and Halazonetis, T. D. (2002) 53BP1 Functions in an ATM-Dependent Checkpoint Pathway that is Constitutively Activated in Human Cancer. Nat Cell Biol. 4, 998-1002.
48. Fernandez-Capetillo, O., Chen, H. T., Celeste, A., Ward, I., Romanienko, P. J., Morales, J. C., Naka, K., Xia, Z., Camerini-Otero, R. D., Motoyama, N., Carpenter, P. B., Bonner, W. M., Chen, J., and Nussenzweig, A. (2002) DNA Damage-Induced G2-M Checkpoint Activation by Histone H2AX and 53BP1. Nat Cell Biol. 4, 993-997.
49. Manis, J. P., Morales, J. C., Xia, Z., Kutok, J. L., Alt, F. W., and Carpenter, P. B. (2004) 53BP1 Links DNA Damage-Response Pathways to Immunoglobulin Heavy Chain Class-Switch Recombination. Nat Immunol. 5, 481-487.
50. Mochan, T. A., Venere, M., DiTullio, R. A.,Jr, and Halazonetis, T. D. (2003) 53BP1 and NFBD1/MDC1-Nbs1 Function in Parallel Interacting Pathways Activating Ataxia-Telangiectasia Mutated (ATM) in Response to DNA Damage. Cancer Res. 63, 8586-8591.
51. Wilson, K. A., and Stern, D. F. (2008) NFBD1/MDC1, 53BP1 and BRCA1 have both Redundant and Unique Roles in the ATM Pathway. Cell Cycle. 7, 3584-3594.
52. Bothmer, A., Robbiani, D. F., Feldhahn, N., Gazumyan, A., Nussenzweig, A., and Nussenzweig, M. C. (2010) 53BP1 Regulates DNA Resection and the Choice between Classical and Alternative End Joining during Class Switch Recombination. J Exp Med. 207, 855-865.
53. Bunting, S. F., Callen, E., Wong, N., Chen, H. T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., Xu, X., Deng, C. X., Finkel, T., Nussenzweig, M., Stark, J. M., and Nussenzweig, A. (2010) 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks. Cell. 141, 243-254.
54. Yamane, A., Robbiani, D. F., Resch, W., Bothmer, A., Nakahashi, H., Oliveira, T., Rommel, P. C., Brown, E. J., Nussenzweig, A., Nussenzweig, M. C., and Casellas, R. (2013) RPA Accumulation during Class Switch Recombination Represents 5'-3' DNA-End Resection during the S-G2/M Phase of the Cell Cycle. Cell Rep. 3, 138-147.
55. Bekker-Jensen, S., and Mailand, N. (2010) Assembly and Function of DNA Double-Strand Break Repair Foci in Mammalian Cells. DNA Repair (Amst). 9, 1219-1228.
56. Celeste, A., Fernandez-Capetillo, O., Kruhlak, M. J., Pilch, D. R., Staudt, D. W., Lee, A., Bonner, R. F., Bonner, W. M., and Nussenzweig, A. (2003) Histone H2AX Phosphorylation is Dispensable for the Initial Recognition of DNA Breaks. Nat Cell Biol. 5, 675-679.
57. Stucki, M., and Jackson, S. P. (2006) GammaH2AX and MDC1: Anchoring the DNA-Damage-Response Machinery to Broken Chromosomes. DNA Repair (Amst). 5, 534-543.
58. Ikura, T., Tashiro, S., Kakino, A., Shima, H., Jacob, N., Amunugama, R., Yoder, K., Izumi, S., Kuraoka, I., Tanaka, K., Kimura, H., Ikura, M., Nishikubo, S., Ito, T., Muto, A., Miyagawa, K., Takeda, S., Fishel, R., Igarashi, K., and Kamiya, K. (2007) DNA Damage-Dependent Acetylation and Ubiquitination of H2AX Enhances Chromatin Dynamics. Mol Cell Biol. 27, 7028-7040.
59. Mallette, F. A., Mattiroli, F., Cui, G., Young, L. C., Hendzel, M. J., Mer, G., Sixma, T. K., and Richard, S. (2012) RNF8- and RNF168-Dependent Degradation of KDM4A/JMJD2A Triggers 53BP1 Recruitment to DNA Damage Sites. EMBO J. 31, 1865-1878.
60. Acs, K., Luijsterburg, M. S., Ackermann, L., Salomons, F. A., Hoppe, T., and Dantuma, N. P. (2011) The AAA-ATPase VCP/p97 Promotes 53BP1 Recruitment by Removing L3MBTL1 from DNA Double-Strand Breaks. Nat Struct Mol Biol. 18, 1345-1350.
61. Murr, R., Loizou, J. I., Yang, Y. G., Cuenin, C., Li, H., Wang, Z. Q., and Herceg, Z. (2006) Histone Acetylation by Trrap-Tip60 Modulates Loading of Repair Proteins and Repair of DNA Double-Strand Breaks. Nat Cell Biol. 8, 91-99.
62. Shibata, A., Barton, O., Noon, A. T., Dahm, K., Deckbar, D., Goodarzi, A. A., Lobrich, M., and Jeggo, P. A. (2010) Role of ATM and the Damage Response Mediator Proteins 53BP1 and MDC1 in the Maintenance of G(2)/M Checkpoint Arrest. Mol Cell Biol. 30, 3371-3383.
63. Coutts, A. S., and La Thangue, N. B. (2005) The p53 Response: Emerging Levels of Co-Factor Complexity. Biochem Biophys Res Commun. 331, 778-785.
64. Ward, I. M., Difilippantonio, S., Minn, K., Mueller, M. D., Molina, J. R., Yu, X., Frisk, C. S., Ried, T., Nussenzweig, A., and Chen, J. (2005) 53BP1 Cooperates with p53 and Functions as a Haploinsufficient Tumor Suppressor in Mice. Mol Cell Biol. 25, 10079-10086.
65. Dip, R., and Naegeli, H. (2005) More than just Strand Breaks: The Recognition of Structural DNA Discontinuities by DNA-Dependent Protein Kinase Catalytic Subunit. FASEB J. 19, 704-715.
66. Rothkamm, K., Kruger, I., Thompson, L. H., and Lobrich, M. (2003) Pathways of DNA Double-Strand Break Repair during the Mammalian Cell Cycle. Mol Cell Biol. 23, 5706-5715.
67. Lieber, M. R. (2008) The Mechanism of Human Nonhomologous DNA End Joining. J Biol Chem. 283, 1-5.
68. Difilippantonio, S., Gapud, E., Wong, N., Huang, C. Y., Mahowald, G., Chen, H. T., Kruhlak, M. J., Callen, E., Livak, F., Nussenzweig, M. C., Sleckman, B. P., and Nussenzweig, A. (2008) 53BP1 Facilitates Long-Range DNA End-Joining during V(D)J Recombination. Nature. 456, 529-533.
69. van Gent, D. C. (2009) Reaching Out for the Other End with p53-Binding Protein 1. Trends Biochem Sci. 34, 226-229.
70. Boboila, C., Yan, C., Wesemann, D. R., Jankovic, M., Wang, J. H., Manis, J., Nussenzweig, A., Nussenzweig, M., and Alt, F. W. (2010) Alternative End-Joining Catalyzes Class Switch Recombination in the Absence of both Ku70 and DNA Ligase 4. J Exp Med. 207, 417-427.
71. Reina-San-Martin, B., Chen, J., Nussenzweig, A., and Nussenzweig, M. C. (2007) Enhanced Intra-Switch Region Recombination during Immunoglobulin Class Switch Recombination in 53BP1-/- B Cells. Eur J Immunol. 37, 235-239.
72. Ramiro, A. R., Jankovic, M., Callen, E., Difilippantonio, S., Chen, H. T., McBride, K. M., Eisenreich, T. R., Chen, J., Dickins, R. A., Lowe, S. W., Nussenzweig, A., and Nussenzweig, M. C. (2006) Role of Genomic Instability and p53 in AID-Induced c-Myc-Igh Translocations. Nature. 440, 105-109.
73. Xie, A., Hartlerode, A., Stucki, M., Odate, S., Puget, N., Kwok, A., Nagaraju, G., Yan, C., Alt, F. W., Chen, J., Jackson, S. P., and Scully, R. (2007) Distinct Roles of Chromatin-Associated Proteins MDC1 and 53BP1 in Mammalian Double-Strand Break Repair. Mol Cell. 28, 1045-1057.
74. Reina-San-Martin, B., Difilippantonio, S., Hanitsch, L., Masilamani, R. F., Nussenzweig, A., and Nussenzweig, M. C. (2003) H2AX is Required for Recombination between Immunoglobulin Switch Regions but Not for Intra-Switch Region Recombination Or Somatic Hypermutation. J Exp Med. 197, 1767-1778.
75. Konishi, A., and de Lange, T. (2008) Cell Cycle Control of Telomere Protection and NHEJ Revealed by a Ts Mutation in the DNA-Binding Domain of TRF2. Genes Dev. 22, 1221-1230.
76. Kakarougkas, A., Ismail, A., Klement, K., Goodarzi, A. A., Conrad, S., Freire, R., Shibata, A., Lobrich, M., and Jeggo, P. A. (2013) Opposing Roles for 53BP1 during Homologous Recombination. Nucleic Acids Res. 41, 9719-9731.
77. Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., Haffty, B. G., Tommiska, J., Blomqvist, C., Drapkin, R., Adams, D. J., Nevanlinna, H., Bartek, J., Tarsounas, M., Ganesan, S., and Jonkers, J. (2010) 53BP1 Loss Rescues BRCA1 Deficiency and is Associated with Triple-Negative and BRCA-Mutated Breast Cancers. Nat Struct Mol Biol. 17, 688-695.
78. Chapman, J. R., Sossick, A. J., Boulton, S. J., and Jackson, S. P. (2012) BRCA1-Associated Exclusion of 53BP1 from DNA Damage Sites Underlies Temporal Control of DNA Repair. J Cell Sci. 125, 3529-3534.
79. Cao, L., Xu, X., Bunting, S. F., Liu, J., Wang, R. H., Cao, L. L., Wu, J. J., Peng, T. N., Chen, J., Nussenzweig, A., Deng, C. X., and Finkel, T. (2009) A Selective Requirement for 53BP1 in the Biological Response to Genomic Instability Induced by Brca1 Deficiency. Mol Cell. 35, 534-541.
80. Jaspers, J. E., Kersbergen, A., Boon, U., Sol, W., van Deemter, L., Zander, S. A., Drost, R., Wientjens, E., Ji, J., Aly, A., Doroshow, J. H., Cranston, A., Martin, N. M., Lau, A., O'Connor, M. J., Ganesan, S., Borst, P., Jonkers, J., and Rottenberg, S. (2013) Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors. Cancer Discov. 3, 68-81.
81. Orsburn, B., Escudero, B., Prakash, M., Gesheva, S., Liu, G., Huso, D. L., and Franco, S. (2010) Differential Requirement for H2AX and 53BP1 in Organismal Development and Genome Maintenance in the Absence of Poly(ADP)Ribosyl Polymerase 1. Mol Cell Biol. 30, 2341-2352.
82. Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., and Helleday, T. (2005) Specific Killing of BRCA2-Deficient Tumours with Inhibitors of Poly(ADP-Ribose) Polymerase. Nature. 434, 913-917.
83. Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., Martin, N. M., Jackson, S. P., Smith, G. C., and Ashworth, A. (2005) Targeting the DNA Repair Defect in BRCA Mutant Cells as a Therapeutic Strategy. Nature. 434, 917-921.
84. Petersen, S., Casellas, R., Reina-San-Martin, B., Chen, H. T., Difilippantonio, M. J., Wilson, P. C., Hanitsch, L., Celeste, A., Muramatsu, M., Pilch, D. R., Redon, C., Ried, T., Bonner, W. M., Honjo, T., Nussenzweig, M. C., and Nussenzweig, A. (2001) AID is Required to Initiate Nbs1/gamma-H2AX Focus Formation and Mutations at Sites of Class Switching. Nature. 414, 660-665.
85. Chen, H. T., Bhandoola, A., Difilippantonio, M. J., Zhu, J., Brown, M. J., Tai, X., Rogakou, E. P., Brotz, T. M., Bonner, W. M., Ried, T., and Nussenzweig, A. (2000) Response to RAG-Mediated VDJ Cleavage by NBS1 and Gamma-H2AX. Science. 290, 1962-1965.
86. Zha, S., Guo, C., Boboila, C., Oksenych, V., Cheng, H. L., Zhang, Y., Wesemann, D. R., Yuen, G., Patel, H., Goff, P. H., Dubois, R. L., and Alt, F. W. (2011) ATM Damage Response and XLF Repair Factor are Functionally Redundant in Joining DNA Breaks. Nature. 469, 250-254.
87. Stavnezer, J., Guikema, J. E., and Schrader, C. E. (2008) Mechanism and Regulation of Class Switch Recombination. Annu Rev Immunol. 26, 261-292.
88. Bothmer, A., Rommel, P. C., Gazumyan, A., Polato, F., Reczek, C. R., Muellenbeck, M. F., Schaetzlein, S., Edelmann, W., Chen, P. L., Brosh, R. M.,Jr, Casellas, R., Ludwig, T., Baer, R., Nussenzweig, A., Nussenzweig, M. C., and Robbiani, D. F. (2013) Mechanism of DNA Resection during Intrachromosomal Recombination and Immunoglobulin Class Switching. J Exp Med. 210, 115-123.
89. Di Virgilio, M., Callen, E., Yamane, A., Zhang, W., Jankovic, M., Gitlin, A. D., Feldhahn, N., Resch, W., Oliveira, T. Y., Chait, B. T., Nussenzweig, A., Casellas, R., Robbiani, D. F., and Nussenzweig, M. C. (2013) Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching. Science. 339, 711-715.
90. Morales, J. C., Franco, S., Murphy, M. M., Bassing, C. H., Mills, K. D., Adams, M. M., Walsh, N. C., Manis, J. P., Rassidakis, G. Z., Alt, F. W., and Carpenter, P. B. (2006) 53BP1 and p53 Synergize to Suppress Genomic Instability and Lymphomagenesis. Proc Natl Acad Sci U S A. 103, 3310-3315.
91. Li, X., Xu, B., Moran, M. S., Zhao, Y., Su, P., Haffty, B. G., Shao, C., and Yang, Q. (2012) 53BP1 Functions as a Tumor Suppressor in Breast Cancer Via the Inhibition of NF-kappaB through miR-146a. Carcinogenesis. 33, 2593-2600.
92. Neboori, H. J., Haffty, B. G., Wu, H., Yang, Q., Aly, A., Goyal, S., Schiff, D., Moran, M. S., Golhar, R., Chen, C., Moore, D., and Ganesan, S. (2012) Low p53 Binding Protein 1 (53BP1) Expression is Associated with Increased Local Recurrence in Breast Cancer Patients Treated with Breast-Conserving Surgery and Radiotherapy. Int J Radiat Oncol Biol Phys. 83, e677-83.
93. Takeyama, K., Monti, S., Manis, J. P., Dal Cin, P., Getz, G., Beroukhim, R., Dutt, S., Aster, J. C., Alt, F. W., Golub, T. R., and Shipp, M. A. (2008) Integrative Analysis Reveals 53BP1 Copy Loss and Decreased Expression in a Subset of Human Diffuse Large B-Cell Lymphomas. Oncogene. 27, 318-322.
94. Lowndes, N. F. (2010) The Interplay between BRCA1 and 53BP1 Influences Death, Aging, Senescence and Cancer. DNA Repair (Amst). 9, 1112-1116.
95. Jankovic, M., Feldhahn, N., Oliveira, T. Y., Silva, I. T., Kieffer-Kwon, K. R., Yamane, A., Resch, W., Klein, I., Robbiani, D. F., Casellas, R., and Nussenzweig, M. C. (2013) 53BP1 Alters the Landscape of DNA Rearrangements and Suppresses AID-Induced B Cell Lymphoma. Mol Cell. 49, 623-631.
96. Stewart, G. S., Stankovic, T., Byrd, P. J., Wechsler, T., Miller, E. S., Huissoon, A., Drayson, M. T., West, S. C., Elledge, S. J., and Taylor, A. M. (2007) RIDDLE Immunodeficiency Syndrome is Linked to Defects in 53BP1-Mediated DNA Damage Signaling. Proc Natl Acad Sci U S A. 104, 16910-16915.
97. Ward, I. M., Minn, K., van Deursen, J., and Chen, J. (2003) P53 Binding Protein 53BP1 is Required for DNA Damage Responses and Tumor Suppression in Mice. Mol Cell Biol. 23, 2556-2563.
98. Enders, A., Short, A., Miosge, L. A., Bergmann, H., Sontani, Y., Bertram, E. M., Whittle, B., Balakishnan, B., Yoshida, K., Sjollema, G., Field, M. A., Andrews, T. D., Hagiwara, H., and Goodnow, C. C. (2014) Zinc-Finger Protein ZFP318 is Essential for Expression of IgD, the Alternatively Spliced Igh Product made by Mature B Lymphocytes. Proc Natl Acad Sci U S A. 111, 4513-4518.
|Science Writers||Anne Murray|
|Authors||Kuan-Wen Wang, Jin Huk Choi, Ming Zeng, Bruce Beutler|
|List |< first << previous [record 17 of 30] next >> last >||